Medtronic partners to reduce stroke death; FDA clears women's fecal incontinence device;

@FierceMedDev: J&J joins forces with JDRF for type 1 diabetes Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: NIH discusses 'precision medicine' genomics initiative and how to build a million-person research cohort. Item | Follow @VarunSaxena2

@EmilyWFierce: Better training for pediatricians could help increase use of IUDs in teenage girls. Story from The Atlantic | Follow @EmilyWFierce

> Arizona State University has spun-out Saccadous, a Scottsdale-based company with eye tracker technology that uses eye movements to noninvasively detect neurological diseases, such as Alzheimer's disease, Cerebral Palsy, Parkinson's disease and even concussions. Story

> The FDA has cleared the Eclipse System from Pelvalon to treat fecal incontinence. In a 61-woman clinical trial, in 80% of women the device reduced the number of episodes by half. The device is an inflatable balloon that is inserted into the vagina and inflated or deflated by the patient on an as-needed basis. Release

> The American Heart Association and the American Stroke Association will collaborate with Medtronic ($MDT) to support the non-profits' goal of reducing death from stroke by 20% by 2020. Release

Biotech News

@FierceBiotech: Eisai wins an early FDA nod for its self-described cancer blockbuster. Report | Follow @FierceBiotech

@JohnCFierce: Biotech boom drives blockbuster VC investments in Boston, San Francisco. Story | Follow @JohnCFierce

@DamianFierce: Eisai exec told WSJ yesterday that lenvatinib approval was "imminent." Well. FDA announcement | Follow @DamianFierce

> The curious case of Item

> Activists want Ariad's CEO out the door, report says. More

> Shire and Valeant are reportedly eyeing $10B bids for Salix. Report

Pharma News

@FiercePharma: UPDATED: Valeant, Shire prep Salix bids. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Teva 'likely' violated FCPA, local laws in Russia, Latin America and elsewhere. Report | Follow @CarlyHFierce

> Activists ready to fight for Ariad CEO's ouster: CNBC. More

> Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU. Article

> England's price watchdog writes off Celgene's Imnovid in final guidance. Story